NEW YORK (GenomeWeb) – Horizon Discovery Group today announced a worldwide co-exclusive distribution agreement with Haplogen Genomics.
The deal provides Horizon access to a high-throughput, affordable cell line engineering service. Haplogen's experience with haploid cell lines and a highly optimized production pipeline allows knockouts for non-essential genes to be generated at hundreds of new isogenic cell lines each month, Horizon said.
The Cambridge, UK-based firm added that it will market Haplogen's collection of more than 700 knockout cell lines and more than 9,000 gene trap mutants to more than 70,000 active academic research labs globally. Biotech and pharma customers will be able to access off-the-shelf or custom cell lines through Horizon by signing a limited label license for a one-year term. Academic customers can access an unlimited term license at a discount of more than 80 percent.
Horizon CEO Darrin Disley said in a statement that the agreement will allow his firm to address the needs of academic labs that to date have not been able to access Horizon's custom gene-editing services. "Haplogen's products and services are highly complementary to our in-house portfolio, including our X-MAN range of diploid isogenic cell lines," he said.
Financial and other terms of the deal were not disclosed.
Haplogen is based in Vienna and provides validated human knockout cell lines.